CLINICAL TRIAL: PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE

临床试验：第 3 阶段研究：低级淋巴组合物环磷酰胺/氟达拉滨

• 批准号: 7951356
• 负责人: CHRISTOPHER EHMANN
• 金额: $ 0.09万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951356
• 关键词: Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide; Funding; Grant; Institution; Lymph; Lymphocyte; Lymphoma; Maintenance; Patients; Phase III Clinical Trials; Research; Research Personnel; Resources; Source; Time; Treatment Protocols; United States National Institutes of Health; Upper arm; fludarabine; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the response rate, time to progression and survival for patients with low-grade lymphoma treated with the Cyclophosphamide/Fludarabine regimen with a control arm of standard CVP. The study will also determine the effect of maintenance with anti-CD20 on time to progression and survival and its effect on lymphocytic number, subsets and quantitative immunoglobin levels over time.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是比较环磷酰胺/氟达拉滨方案和标准CVP对照组治疗低度恶性淋巴瘤患者的有效率、进展时间和生存时间。这项研究还将确定使用抗CD20维持治疗对进展时间和存活率的影响，以及随着时间的推移对淋巴细胞数量、亚群和定量免疫球蛋白水平的影响。